Dupuytren’s disease News and Research

RSS
Trial shows the efficacy of anti-TNF drug for patients with early-stage Dupuytren's disease

Trial shows the efficacy of anti-TNF drug for patients with early-stage Dupuytren's disease

Study offers new hope for people with disabling Dupuytren's disease

Study offers new hope for people with disabling Dupuytren's disease

Endo Announces Updated XIAFLEX® Label in Patients with Dupuytren’s Contracture

Endo Announces Updated XIAFLEX® Label in Patients with Dupuytren’s Contracture

Revolutionary new treatment for crippling hand conditions

Revolutionary new treatment for crippling hand conditions

Study compares needle fasciotomy and conventional surgery for Dupuytren's contractures

Study compares needle fasciotomy and conventional surgery for Dupuytren's contractures

Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects

Top-line results from Auxilium XIAFLEX palpable cord study in Dupuytren's contracture subjects

Auxilium to receive $30 million from Pfizer following XIAPEX sale in EU market

Auxilium to receive $30 million from Pfizer following XIAPEX sale in EU market

CME program for understanding latest treatment and research on Dupuytren's disease

CME program for understanding latest treatment and research on Dupuytren's disease

FDA approves Xiaflex drug for treatment of Dupuytren's contracture

FDA approves Xiaflex drug for treatment of Dupuytren's contracture

Scientific/technical review for XIAFLEX' European MAA commences

Scientific/technical review for XIAFLEX' European MAA commences

BioSpecifics Technologies revenues increases by 100% for the third quarter ended September 30, 2009

BioSpecifics Technologies revenues increases by 100% for the third quarter ended September 30, 2009

BioSpecifics Technologies' XIAFLEX receives marketing approval from FDA

BioSpecifics Technologies' XIAFLEX receives marketing approval from FDA

Phase III clinical trial results of XIAFLEX published in a journal

Phase III clinical trial results of XIAFLEX published in a journal

CORD I phase III clinical trial results of XIAFLEX published

CORD I phase III clinical trial results of XIAFLEX published

New method for treating hand disorder discovered

New method for treating hand disorder discovered

Biospecifics Technologies reports Q2 2009 financials

Biospecifics Technologies reports Q2 2009 financials

Genetic influences behind Dupuytren's disease or contracture

Genetic influences behind Dupuytren's disease or contracture

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.